ArticleCell reports2025
Allele-specific zinc metalloprotease B influences cardiac damage during invasive pneumococcal disease.
Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
During severe infection, Streptococcuspneumoniae invades the myocardium, causing life-threatening cardiac complications. Bacterial genome-wide association studies implicate a specific allele of the gene encoding zinc metalloprotease B (ZmpB) as a key determinant of S. pneumoniae-mediated cardiac damage. In mouse models, ZmpB-deficient S. pneumoniae show reduced cardiac microlesion formation, and immunization with recombinant ZmpB confers protection. ZmpB-deficient S. pneumoniae are also attenuated in their ability to impair contractility of human induced pluripotent stem cell (iPSC)-derived 3D cardiac organoids and exhibit reduced invasion and intracellular survival in mouse cardiac vascular endothelial cell (MCEC) and atrial cardiomyocyte (HL-1) cell lines. ZmpB varies in the number of FIVAR (found in various architectures) domains at its N terminus, with FIVAR-rich variants being prevalent in strains linked to human cardiac complications. Using clinical isolates and isogenic mutants producing ZmpB with different FIVAR domain counts, we confirm this association. These findings indicate that FIVAR-rich ZmpB variants enhance S. pneumoniae's invasive capacity, increasing the risk of cardiac pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.